Herberts CA - Search Results

1

Risk factors in the development of stem cell therapy.

Herberts CA, Kwa MS, Hermsen HP. Herberts CA, et al. J Transl Med. 2011 Mar 22;9:29. doi: 10.1186/1479-5876-9-29. J Transl Med. 2011. PMID: 21418664 Free PMC article.

2

Animal-free applications in the development of cell-based therapies.

van Meer P, Theunissen P, van den Hoorn T, Herberts C, van der Laan JW. van Meer P, et al. Br J Clin Pharmacol. 2021 Jun;87(6):2425-2427. doi: 10.1111/bcp.14544. Epub 2020 Sep 15. Br J Clin Pharmacol. 2021. PMID: 32935350 Free article. No abstract available.

3

Development of cell therapy medicinal products by academic institutes.

de Wilde S, Guchelaar HJ, Herberts C, Lowdell M, Hildebrandt M, Zandvliet M, Meij P. de Wilde S, et al. Drug Discov Today. 2016 Aug;21(8):1206-12. doi: 10.1016/j.drudis.2016.04.016. Epub 2016 Apr 23. Drug Discov Today. 2016. PMID: 27117349

4

Results from a horizon scan on risks associated with transplantation of human organs, tissues and cells: from donor to patient.

Herberts CA, Park MV, Pot JW, de Vries CG. Herberts CA, et al. Cell Tissue Bank. 2015 Mar;16(1):1-17. doi: 10.1007/s10561-014-9450-0. Epub 2014 May 1. Cell Tissue Bank. 2015. PMID: 24789705 Review.

5

Mining scientific advice reports on cell-based products: Insight into the nonclinical development program.

van den Hoorn T, Nakchedi T, de Wolf ACMT, Pasmooij AMG, van der Laan JW, Herberts CA. van den Hoorn T, et al. Among authors: herberts ca. Br J Clin Pharmacol. 2021 Jun;87(6):2465-2474. doi: 10.1111/bcp.14515. Epub 2020 Oct 12. Br J Clin Pharmacol. 2021. PMID: 32790909 Free article.

6

Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider.

Sato Y, Bando H, Di Piazza M, Gowing G, Herberts C, Jackman S, Leoni G, Libertini S, MacLachlan T, McBlane JW, Pereira Mouriès L, Sharpe M, Shingleton W, Surmacz-Cordle B, Yamamoto K, van der Laan JW. Sato Y, et al. Cytotherapy. 2019 Nov;21(11):1095-1111. doi: 10.1016/j.jcyt.2019.10.001. Epub 2019 Nov 9. Cytotherapy. 2019. PMID: 31711733 Free article. Review.

7

Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.

de Wolf ACMT, Herberts CA, Hoefnagel MHN. de Wolf ACMT, et al. Among authors: herberts ca. Front Med (Lausanne). 2020 Apr 2;7:91. doi: 10.3389/fmed.2020.00091. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32300597 Free PMC article.

8

Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection.

Herberts CA, van Gaans-van den Brink J, van der Heeft E, van Wijk M, Hoekman J, Jaye A, Poelen MC, Boog CJ, Roholl PJ, Whittle H, de Jong AP, van Els CA. Herberts CA, et al. Hum Immunol. 2003 Jan;64(1):44-55. doi: 10.1016/s0198-8859(02)00707-3. Hum Immunol. 2003. PMID: 12507814

9

EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.

Karres D, Ali S, van Hennik PB, Straus S, Josephson F, Thole G, Glerum PJ, Herberts C, Babae N, Herold R, Papadouli I, Pignatti F. Karres D, et al. Oncologist. 2020 Jun;25(6):e976-e981. doi: 10.1634/theoncologist.2019-0898. Epub 2020 Mar 10. Oncologist. 2020. PMID: 32154610 Free PMC article. Review.

10

New adjuvanted vaccines in pregnancy: what is known about their safety?

Herberts C, Melgert B, van der Laan JW, Faas M. Herberts C, et al. Expert Rev Vaccines. 2010 Dec;9(12):1411-22. doi: 10.1586/erv.10.133. Expert Rev Vaccines. 2010. PMID: 21105777 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters